Form 4: Verona Pharma Director Anders Ullman Awarded 96,000 Restricted Share Units

Director Anders Ullman receives 96,000 Restricted Share Units (RSUs) in Verona Pharma plc, vesting quarterly starting August 1, 2025.

Summary

• Anders Ullman, a director of Verona Pharma plc, was granted 96,000 Restricted Share Units (RSUs) on April 25, 2025.
• Each RSU represents the right to receive one American Depositary Share (ADS), and each ADS represents eight Ordinary Shares of Verona Pharma.
• The RSUs will vest in four equal installments of 25% each, on August 1, 2025, November 1, 2025, February 1, 2026, and May 1, 2026.
• Vesting is contingent upon Ullman's continued service to Verona Pharma on each vesting date.
• The reporting person has direct ownership of the derivative securities.
• The price of the derivative security is $0.

Sentiment

Score: 7

Explanation: The sentiment is neutral to positive. It reflects a standard compensation practice that aligns management interests with shareholders. The vesting schedule promotes long-term commitment.

Positives

• The grant of RSUs aligns the director's interests with those of the shareholders, incentivizing continued service and contribution to the company's success.
• The vesting schedule encourages long-term commitment from the director.

Risks

• The value of the RSUs is dependent on the future performance of Verona Pharma's stock price.
• If Anders Ullman ceases to be a director of Verona Pharma before the vesting dates, the unvested RSUs will be forfeited.

Future Outlook

The document does not contain specific forward-looking statements beyond the vesting schedule of the RSUs.

Industry Context

Equity compensation is a common practice in the pharmaceutical industry to attract and retain key personnel, aligning their interests with the long-term success of the company.

Comparison to Industry Standards

• RSU grants are a standard form of executive compensation in the pharmaceutical industry, often used by companies like AstraZeneca, GlaxoSmithKline, and Novartis to incentivize performance and retain key talent.
• The vesting schedule of 25% per quarter is a typical arrangement, similar to those found in other publicly traded biotech firms.

Stakeholder Impact

• Shareholders may view the RSU grant positively as it incentivizes the director to work towards increasing shareholder value.
• Employees may see this as a positive sign of the company's commitment to its leadership.

Key Dates

Keywords

Restricted Share Units, RSU, Verona Pharma, Director, Anders Ullman, Vesting, ADS, Ordinary Shares, Compensation, Equity